PL2424356T3 - Stabilna farmaceutyczna kompozycja i sposoby jej stosowania - Google Patents

Stabilna farmaceutyczna kompozycja i sposoby jej stosowania

Info

Publication number
PL2424356T3
PL2424356T3 PL10770322T PL10770322T PL2424356T3 PL 2424356 T3 PL2424356 T3 PL 2424356T3 PL 10770322 T PL10770322 T PL 10770322T PL 10770322 T PL10770322 T PL 10770322T PL 2424356 T3 PL2424356 T3 PL 2424356T3
Authority
PL
Poland
Prior art keywords
methods
same
pharmaceutical composition
stable pharmaceutical
stable
Prior art date
Application number
PL10770322T
Other languages
English (en)
Inventor
Mehar Manku
Original Assignee
Amarin Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2424356(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharmaceuticals Ireland Limited filed Critical Amarin Pharmaceuticals Ireland Limited
Publication of PL2424356T3 publication Critical patent/PL2424356T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
PL10770322T 2009-04-29 2010-04-29 Stabilna farmaceutyczna kompozycja i sposoby jej stosowania PL2424356T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17376309P 2009-04-29 2009-04-29
PCT/US2010/032952 WO2010127103A1 (en) 2009-04-29 2010-04-29 Stable pharmaceutical composition and methods of using same
EP10770322.5A EP2424356B1 (en) 2009-04-29 2010-04-29 Stable pharmaceutical composition and methods of using same

Publications (1)

Publication Number Publication Date
PL2424356T3 true PL2424356T3 (pl) 2018-03-30

Family

ID=43030519

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17168056.4T PL3278665T3 (pl) 2009-04-29 2010-04-29 Stabilna kompozycja farmaceutyczna i sposoby jej zastosowania
PL10770322T PL2424356T3 (pl) 2009-04-29 2010-04-29 Stabilna farmaceutyczna kompozycja i sposoby jej stosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17168056.4T PL3278665T3 (pl) 2009-04-29 2010-04-29 Stabilna kompozycja farmaceutyczna i sposoby jej zastosowania

Country Status (27)

Country Link
US (30) US20120100208A1 (pl)
EP (3) EP3797591A1 (pl)
KR (1) KR101343249B1 (pl)
CN (2) CN104856985B (pl)
AU (1) AU2010241571B2 (pl)
BR (1) BRPI1011876B1 (pl)
CA (1) CA2759284C (pl)
CO (1) CO6470838A2 (pl)
CY (2) CY1119596T1 (pl)
DK (2) DK2424356T3 (pl)
ES (2) ES2827204T3 (pl)
HK (3) HK1165944A1 (pl)
HR (2) HRP20171766T1 (pl)
HU (2) HUE034941T2 (pl)
LT (2) LT2424356T (pl)
MX (2) MX350088B (pl)
MY (1) MY157120A (pl)
NO (1) NO2424356T3 (pl)
NZ (2) NZ595852A (pl)
PH (1) PH12016500216B1 (pl)
PL (2) PL3278665T3 (pl)
PT (2) PT3278665T (pl)
RU (2) RU2538691C2 (pl)
SG (3) SG10201605794PA (pl)
SI (2) SI2424356T1 (pl)
WO (1) WO2010127103A1 (pl)
ZA (1) ZA201107699B (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5924834B2 (ja) * 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
ES2459951T3 (es) 2009-12-30 2014-05-13 Basf Pharma (Callanish) Limited Proceso de separación cromatográfico de lecho móvil simulado para la purificación de ácidos grasos poliinsaturados
WO2011087981A2 (en) * 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
IT1401461B1 (it) * 2010-06-14 2013-07-26 Bruzzese Uso di composizioni di acidi grassi polinsaturi selezionati per il trattamento dello scompenso cardiaco diastolico.
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20140039053A1 (en) * 2011-02-07 2014-02-06 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for diastolic congestive heart failure
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
ES2685703T3 (es) 2012-01-06 2018-10-10 Omthera Pharmaceuticals Inc. Composiciones enriquecidas en DPA de ácidos grasos omega-3 poliinsaturados en forma de ácido libre
KR101681907B1 (ko) * 2012-02-27 2016-12-12 주식회사 케어사이드 혈액 순환 촉진 및 피부 질환 개선용 조성물
TW201347754A (zh) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc 史他汀及ω－３脂肪酸之組合物
US20130324607A1 (en) * 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
MX2015000138A (es) 2012-06-29 2015-09-07 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
EP3888646A1 (en) * 2012-12-06 2021-10-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US9180091B2 (en) * 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014134466A1 (en) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US20140249214A1 (en) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of warfarin and ethyl eicosapentaenoate
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014179341A1 (en) * 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Treatment with omega-3 fatty acid compositions
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015021141A1 (en) * 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2926335C (en) 2013-10-30 2021-11-23 Banner Life Sciences Llc Enteric soft capsules comprising polyunsaturated fatty acids
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
WO2015130998A1 (en) 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10538013B2 (en) 2014-05-08 2020-01-21 United Technologies Corporation Integral ceramic matrix composite fastener with non-polymer rigidization
US10371011B2 (en) 2014-05-08 2019-08-06 United Technologies Corporation Integral ceramic matrix composite fastener with polymer rigidization
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CA2950311C (en) 2014-06-23 2019-05-14 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) * 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190385718A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
JP7020756B2 (ja) 2018-09-24 2022-02-16 アマリン ファーマシューティカルズ アイルランド リミテッド 対象の心血管イベントのリスクを低減する方法
US10841617B2 (en) 2018-11-27 2020-11-17 Semiconductor Components Industries, Llc Methods and apparatus for successive intra block prediction
US11405206B2 (en) 2018-12-30 2022-08-02 Beijing Voyager Technology Co., Ltd. Systems and methods for managing a compromised autonomous vehicle server
US11418351B2 (en) * 2018-12-30 2022-08-16 Beijing Voyager Technology, Inc. Systems and methods for managing a compromised autonomous vehicle server
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (352)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527784B2 (en) 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
JPS57112593A (en) 1980-12-26 1982-07-13 Koken Boring Machine Co Lathe drill
US4377526A (en) * 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
JPS58175894U (ja) 1982-05-17 1983-11-24 荏原インフイルコ株式会社 スクリユ−プレス型脱水機
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS6135356A (ja) 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
AU602376B2 (en) 1986-12-26 1990-10-11 Sagami Chemical Research Center Process for production of eicosapentaenoic acid
JPS63185390A (ja) 1987-01-27 1988-07-30 Suntory Ltd 藻類によるエイコサペンタエン酸の製造方法
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CA1338683C (en) * 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) * 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
DK95490D0 (da) 1990-04-18 1990-04-18 Novo Nordisk As Fremgangsmaade til fremstilling af triglycerid og triglyceridsammensaetning
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) * 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
AU2384292A (en) * 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) * 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
JPH0692847A (ja) 1992-09-11 1994-04-05 Mochida Pharmaceut Co Ltd 骨粗鬆症治療剤
WO1994010125A1 (en) 1992-10-27 1994-05-11 Sandoz Ltd. Glycerin derivatives and uses thereof
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU7053494A (en) 1993-06-04 1995-01-03 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9318611D0 (en) 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JP3325995B2 (ja) 1994-02-28 2002-09-17 ミサワホーム株式会社 パネル接合構造
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JP3368100B2 (ja) 1994-06-02 2003-01-20 キヤノン株式会社 静電荷像現像用トナー
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JP2780154B2 (ja) 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
JPH0840981A (ja) 1995-03-24 1996-02-13 Nissui Pharm Co Ltd エイコサペンタエノイルグリセライド
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH0959206A (ja) 1995-08-25 1997-03-04 Nippon Oil & Fats Co Ltd エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
JP3552810B2 (ja) 1995-09-27 2004-08-11 松下電器産業株式会社 部品供給部の部品一括交換方法と装置
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6248398B1 (en) 1996-05-22 2001-06-19 Applied Materials, Inc. Coater having a controllable pressurized process chamber for semiconductor processing
TW425285B (en) * 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
CN1109543C (zh) 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
JP4176166B2 (ja) 1996-11-15 2008-11-05 持田製薬株式会社 横紋筋融解症治療剤
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
US6362236B1 (en) 1997-11-25 2002-03-26 Warner-Lambert Company Inhibition of lipoprotein oxidation
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
NZ500703A (en) 1998-11-04 2001-06-29 F Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
CA2366318A1 (en) 1999-03-03 2000-09-08 Ida Royalty Aps Novel pharmaceutical, dietary and cosmetic compositions comprising zinger officinale roscoe, eicosapentaenoic acid and/or docosahexaenoic acid
WO2000051444A1 (fr) 1999-03-04 2000-09-08 Suntory Limited Utilisation d'une matiere contenant de l'acide docosapentaenoique
US20020054871A1 (en) 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
CA2311974A1 (en) 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
EP1072198B1 (de) * 1999-07-28 2008-05-14 SWISS CAPS Rechte und Lizenzen AG Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung
EP1211955A1 (en) * 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP4170542B2 (ja) 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
EP1125914A1 (en) 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Process for separating and purifying eicosapentaenoic acid or its ester
WO2001068136A1 (fr) 2000-03-17 2001-09-20 Ajinomoto Co., Inc. Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
JP4391673B2 (ja) 2000-08-08 2009-12-24 花王株式会社 油脂組成物
HUP0303083A3 (en) 2000-08-15 2005-05-30 Pfizer Prod Inc Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use
US20030195246A1 (en) 2000-08-16 2003-10-16 Takeshi Nakamura Seamless soft capsule preparations containing dihydrobenzofuran derivatives
US6383482B1 (en) 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
GB0101198D0 (en) 2001-01-17 2001-02-28 Scherer Technologies Inc R P Ingestible compositions containing an odoriferous oil
JP2005503533A (ja) 2001-01-19 2005-02-03 ケンブリッジ サイエンティフィック， インコーポレイテッド 骨粗鬆症の診断方法および処置方法
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
IL143379A (en) 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
KR20040004652A (ko) * 2001-05-30 2004-01-13 랙스데일 리미티드 조효소 ｑ 및 에이코사펜타에노산（ｅｐａ）
US20120214771A1 (en) 2001-07-27 2012-08-23 Fontini Sampalis Compositions for treatment of cardiometabolic disorders
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
JP2003306690A (ja) 2002-02-18 2003-10-31 Nooburu:Kk 多価不飽和脂肪酸含有油脂組成物
HUP0200686A2 (hu) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
AU2003229993B2 (en) 2002-05-03 2008-07-24 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
WO2003103582A2 (en) 2002-06-05 2003-12-18 Ivax Corporation Reduction of gelatin cross-linking
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US20040001874A1 (en) 2002-06-24 2004-01-01 Vital Living, Inc. Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
US20040048919A1 (en) 2002-07-02 2004-03-11 Dreon Darlene M. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US20060211761A1 (en) 2002-07-08 2006-09-21 Yatendra Kumar Hmg-coa-reductase inhibitors
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
AU2003257550A1 (en) * 2002-08-20 2004-03-11 Nikken Chemicals Co., Ltd. Soft capsule preparation
KR100539027B1 (ko) 2002-10-18 2005-12-26 현대모비스 주식회사 차량의 조향각 검출 장치
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
KR101045035B1 (ko) * 2002-11-22 2011-06-30 니폰스이산가부시키가이샤 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는조성물
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2512666A1 (en) 2003-01-08 2004-07-29 Flacco-Nesselroad Family Trust Combination therapy for anticoagulation
GB0301701D0 (en) 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
EP1587377A2 (en) 2003-01-31 2005-10-26 The Procter & Gamble Company Means for improving the appearance of mammalian keratinous tissue
EP1602372B1 (en) 2003-02-07 2016-08-31 Mochida Pharmaceutical Co., Ltd. Drug for improving prognosis for subarachnoid hemorrhage
WO2004073706A1 (ja) 2003-02-21 2004-09-02 Mochida Pharmaceutical Co., Ltd. リバビリン／インターフェロン併用療法の副作用軽減剤
EP1603551A2 (en) 2003-03-05 2005-12-14 Solvay Pharmaceuticals GmbH Use of omega-3-fatty acids in the treatment of diabetic patients
US20060159746A1 (en) 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
WO2004112777A1 (ja) 2003-06-20 2004-12-29 Mochida Pharmaceutical Co., Ltd. 下肢静脈瘤予防・治療用組成物
US20050042214A1 (en) 2003-07-15 2005-02-24 Gershwin M. Eric Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
US20060134206A1 (en) 2003-07-24 2006-06-22 Iyer Eswaran K Oral compositions for treatment of diseases
IL158600A (en) 2003-10-26 2015-07-30 Hermona Soreq Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
CA2542574C (en) 2003-11-12 2014-03-18 E. I. Du Pont De Nemours And Company Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
EP1711173A2 (en) * 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1591114A1 (en) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US20050272095A1 (en) 2004-05-19 2005-12-08 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
TW200613009A (en) 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
WO2006017627A2 (en) 2004-08-06 2006-02-16 Barry Sears Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
US20090042979A1 (en) 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US9452150B2 (en) 2004-08-18 2016-09-27 Mochida Pharmaceutical Co., Ltd. Jelly composition
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
EP1791954A1 (en) 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
WO2006035417A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
WO2006085144A2 (en) 2004-10-15 2006-08-17 Photonz Corporation Limited Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
CN101098690A (zh) 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US20090239927A1 (en) 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
KR101356335B1 (ko) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20080200707A1 (en) 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
CA2593768C (en) 2005-01-04 2014-02-18 Mochida Pharmaceutical Co., Ltd. Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
AU2006204334B2 (en) 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20060172012A1 (en) 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060189682A1 (en) 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
CA2598273A1 (en) 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20100254951A1 (en) 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
EP1861087A4 (en) 2005-03-08 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
JP5134916B2 (ja) 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
EP1790339B1 (en) 2005-07-08 2014-06-04 Mochida Pharmaceutical Co., Ltd. Composition for prevention of occurrence of cardiovascular event
JP2009515815A (ja) 2005-07-18 2009-04-16 レリアント ファーマスーティカルズ インコーポレイテッド アゼチジノン系コレステロール吸収阻害剤及びオメガ−３脂肪酸を用いた治療、並びにそれらの併用品
US7628027B2 (en) 2005-07-19 2009-12-08 Hussmann Corporation Refrigeration system with mechanical subcooling
RU2290185C1 (ru) 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
WO2007016256A2 (en) 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
RU2302248C2 (ru) 2005-08-30 2007-07-10 Федеральное государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр Средство, обладающее липидкорригирующими, гипокоагуляционными и антиоксидантными свойствами
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2007051065A2 (en) 2005-10-28 2007-05-03 Numerate, Inc. Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070105793A1 (en) 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
EP1946755B1 (en) 2005-11-11 2017-03-15 Mochida Pharmaceutical Co., Ltd. Jelly composition
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
US20070116758A1 (en) 2005-11-21 2007-05-24 Dafna Dlugatch Atorvastatin formulation
ES2511772T3 (es) * 2005-12-20 2014-10-23 Cenestra, Llc Formulaciones de ácidos grasos omega-3
PT1800675E (pt) 2005-12-23 2011-08-30 Nutricia Nv COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA
US20070265340A1 (en) 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
US20070202159A1 (en) 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
WO2007091338A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
JP5069448B2 (ja) 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP5628480B2 (ja) 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー 医薬成分を含有するコーティングカプセル
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
ES2500063T3 (es) 2006-05-31 2014-09-29 Mochida Pharmaceutical Co., Ltd. Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
US20070292501A1 (en) 2006-06-05 2007-12-20 Udell Ronald G Chewable soft gelatin capsules
AU2007270135B9 (en) 2006-07-05 2013-06-27 Fermentalg Production of ultrapure EPA and polar lipids from largely heterotrophic culture
WO2008012329A2 (en) * 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (ru) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
EP2083802A2 (en) * 2006-10-13 2009-08-05 Reliant Pharmaceuticals, Inc. Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
JP2010506920A (ja) 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2008088030A1 (ja) 2007-01-17 2008-07-24 Mochida Pharmaceutical Co., Ltd. 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
CA2676485A1 (en) 2007-01-23 2008-07-31 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
US20080185198A1 (en) 2007-02-02 2008-08-07 Steven Mark Jones Next generation hybrid III parallel/series hybrid system
ES2561482T3 (es) 2007-02-15 2016-02-26 Centre De Recherche Sur Les Biotechnologies Marine Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos
WO2008106787A1 (en) * 2007-03-06 2008-09-12 Bioriginal Food & Science Corporation Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2008115529A1 (en) 2007-03-20 2008-09-25 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids and cetp inhibitors
WO2008145170A1 (de) 2007-05-31 2008-12-04 Siemens Aktiengesellschaft Verfahren zum konfigurieren einer automatisierungsanlage
US20080299187A1 (en) 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
CN102552213A (zh) * 2007-06-29 2012-07-11 武田药品工业株式会社 无缝胶囊
EP2205231A1 (en) 2007-10-01 2010-07-14 NeuroSearch A/S Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
KR100888133B1 (ko) 2007-10-02 2009-03-13 에스케이에너지 주식회사 4종의 금속성분으로 구성된 다성분계 비스무스몰리브데이트 촉매 제조방법 및 상기촉매를 이용하여1,3-부타디엔을 제조하는 방법
WO2009085388A2 (en) 2007-12-20 2009-07-09 Abbott Laboratories Stable nutritional powder
US8361534B2 (en) 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
NZ600720A (en) 2008-01-10 2012-12-21 Takeda Pharmaceutical A Seamless Capsule For A Liquid Pharmaceutical Composition
US20090182049A1 (en) * 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
EP2291499B1 (en) 2008-05-15 2020-02-12 Basf As Krill oil process
US20110118350A1 (en) 2008-05-20 2011-05-19 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
JPWO2009151125A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
US20110082119A1 (en) 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
EP2308493A4 (en) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
JP5924834B2 (ja) 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
CA2738985A1 (en) 2008-09-30 2010-04-08 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for hepatitis c
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
WO2010119319A1 (en) 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US8241672B2 (en) 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2010117951A1 (en) 2009-04-06 2010-10-14 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20120100208A1 (en) * 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US8618168B2 (en) 2009-05-22 2013-12-31 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of OMEGA3 fatty acid
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
RU2402326C1 (ru) 2009-06-22 2010-10-27 Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) Способ коррекции инсулинорезистентности при метаболическом синдроме
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
DK2473045T3 (en) 2009-09-01 2016-12-12 Catabasis Pharmaceuticals Inc Niacin-FATTY ACID CONJUGATES AND THEIR USES
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
WO2011046204A1 (ja) 2009-10-16 2011-04-21 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
WO2011085211A1 (en) 2010-01-08 2011-07-14 Catabasis Pharmaceuticals, Inc. Fatty acid fumarate derivatives and their uses
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
AU2011222544A1 (en) 2010-03-04 2012-09-27 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8846321B2 (en) 2010-03-12 2014-09-30 President And Fellows Of Harvard College Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
EP2566350B1 (en) 2010-05-05 2016-05-04 St. Giles Foods Limited Edible compositions and methods of manufacturing edible compositions
JP5829607B2 (ja) 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤
WO2012032414A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US20130260403A1 (en) 2010-10-20 2013-10-03 GlycoMark Inc. Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
WO2012063820A1 (ja) 2010-11-09 2012-05-18 持田製薬株式会社 血糖値上昇抑制剤
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2502506A1 (en) 2011-03-21 2012-09-26 Abbott Laboratories Methods for improving bone health in infants using long chain polyunsaturated fatty acids
KR101310710B1 (ko) 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8660662B2 (en) 2011-04-22 2014-02-25 Medtronic, Inc. Low impedance, low modulus wire configurations for a medical device
MY162715A (en) 2011-04-27 2017-07-14 Ionis Pharmaceuticals Inc Modulation of apolipoprotein ciii (apociii) expression
CN103957903A (zh) 2011-09-15 2014-07-30 翁特拉制药公司 用于治疗、逆转、抑制或预防对抗血小板治疗的耐受性的方法和组合物
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2792746A4 (en) 2011-12-12 2015-09-16 Nat Cerebral & Cardiovascular Ct OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
WO2013100089A1 (ja) 2011-12-28 2013-07-04 株式会社明治 保存安定性に優れた口腔用抗菌剤および口腔ケア用組成物
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
WO2013136277A1 (en) 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases
MX359711B (es) 2012-03-30 2018-10-08 Sancilio & Company Inc Composiciones de éster de ácido graso omega-3.
TW201347754A (zh) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc 史他汀及ω－３脂肪酸之組合物
KR102125034B1 (ko) 2012-05-15 2020-06-19 모치다 세이야쿠 가부시키가이샤 고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
EP2854951B1 (de) 2012-05-30 2016-09-07 Clariant International Ltd. Zusammensetzung enthaltend aminosäuretenside, betaine und n-methyl-n-acylglucamine mit verbesserter schaumqualität und höherer viskosität
US20130324607A1 (en) 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
US20140080850A1 (en) 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140004183A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
RU2015102808A (ru) 2012-06-29 2016-08-20 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения педиатрического метаболического синдрома
US20150157593A1 (en) 2012-06-29 2015-06-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
US20140005265A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
MX2015000138A (es) 2012-06-29 2015-09-07 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
KR102103426B1 (ko) 2012-09-28 2020-04-22 모치다 세이야쿠 가부시키가이샤 당뇨병 신규 발병 저감용 조성물
EP2719382A1 (en) 2012-10-12 2014-04-16 Mochida Pharmaceutical Co., Ltd. Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140213648A1 (en) 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US20140221676A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US20140221358A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221452A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140242216A1 (en) 2013-02-24 2014-08-28 Mead Johnson Nutrition Company Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
US20140249225A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20140249214A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of warfarin and ethyl eicosapentaenoate
WO2014134466A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US20140249220A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
US9661874B2 (en) 2013-03-11 2017-05-30 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US20140255537A1 (en) 2013-03-11 2014-09-11 Mead Johnson Nutrition Company Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
US20140271907A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140275252A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Methods of treating traumatic brain injury
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014179325A1 (en) 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
US20140357717A1 (en) 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20160135702A1 (en) 2013-06-21 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Techniques for Predicting Cardiac Arrhythmias Based on Signals from Leads of Electrocardiography
EP3023099B1 (en) 2013-07-18 2020-09-30 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of -3 fatty acid
CA2918336C (en) 2013-07-18 2022-05-24 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
WO2015021141A1 (en) 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
US20150051282A1 (en) 2013-08-14 2015-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US20150073050A1 (en) 2013-09-09 2015-03-12 Amarin Pharmaceuticals Ireland Limited Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
US20160213639A1 (en) 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2764467T3 (es) 2014-04-11 2020-06-03 Cymabay Therapeutics Inc Tratamiento de NAFLD y NASH
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US20170213648A1 (en) 2014-08-01 2017-07-27 Western Michigan University Research Foundation Self-supported electronic devices
EP3248599B1 (en) 2015-01-21 2022-07-06 Mochida Pharmaceutical Co., Ltd. Omega-3 fatty acid self-emulsifying composition
JP6514720B2 (ja) 2015-01-21 2019-05-15 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
WO2016140949A1 (en) 2015-03-02 2016-09-09 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20170151202A1 (en) 2015-09-09 2017-06-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
SI3275438T1 (sl) 2016-07-29 2021-05-31 Kowa Company, Ltd. Metode preprečevanja kardiovaskularnih dogodkov pri dislipidemični populaciji z rezidualnim tveganjem
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US20190054054A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods reducing or preventing oxidation of high density lipoprotein (HDL)
US20190054058A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods of Treating or Preventing Bone Loss
US20190209506A1 (en) 2018-01-09 2019-07-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190275057A1 (en) 2018-03-06 2019-09-12 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
EP3836914A4 (en) 2018-08-17 2022-05-18 Amarin Pharmaceuticals Ireland Limited METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A SUBJECT TREATED WITH STATINS
JP7020756B2 (ja) 2018-09-24 2022-02-16 アマリン ファーマシューティカルズ アイルランド リミテッド 対象の心血管イベントのリスクを低減する方法
MX2021003264A (es) 2018-09-26 2021-05-12 Amarin Pharmaceuticals Ie Ltd Composiciones y metodos para tratar o prevenir enfermedades y/o trastornos causados por la exposicion a la contaminacion del aire.
TW202045154A (zh) 2019-02-15 2020-12-16 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 藉由增加血清及血漿epa及dpa含量來降低經他汀治療之受試者之心血管事件之風險的方法

Also Published As

Publication number Publication date
PH12016500216A1 (en) 2018-01-29
US20180280334A1 (en) 2018-10-04
HRP20201830T1 (hr) 2021-01-08
AU2010241571A1 (en) 2011-11-10
US11213504B2 (en) 2022-01-04
BRPI1011876A2 (pt) 2015-09-22
PT3278665T (pt) 2020-11-19
DK3278665T3 (da) 2020-11-30
US10842766B2 (en) 2020-11-24
US20130011472A1 (en) 2013-01-10
US20160213636A1 (en) 2016-07-28
US20130171251A1 (en) 2013-07-04
US8663662B2 (en) 2014-03-04
US8703185B2 (en) 2014-04-22
EP2424356A4 (en) 2012-09-19
US20200405675A1 (en) 2020-12-31
US9060982B2 (en) 2015-06-23
US20100278879A1 (en) 2010-11-04
ZA201107699B (en) 2012-12-27
US11147787B2 (en) 2021-10-19
US20210113510A1 (en) 2021-04-22
US20200297683A1 (en) 2020-09-24
EP3278665B1 (en) 2020-09-09
PT2424356T (pt) 2017-11-23
US8623406B2 (en) 2014-01-07
US8454994B2 (en) 2013-06-04
MX350088B (es) 2017-08-25
SI3278665T1 (sl) 2021-01-29
NO2424356T3 (pl) 2018-01-20
US8298554B2 (en) 2012-10-30
US20140088194A1 (en) 2014-03-27
KR20120000109A (ko) 2012-01-03
NZ595852A (en) 2014-07-25
US20130090383A1 (en) 2013-04-11
US8617593B2 (en) 2013-12-31
US20200113862A1 (en) 2020-04-16
US20130252990A1 (en) 2013-09-26
RU2014131716A (ru) 2016-02-20
US9072715B2 (en) 2015-07-07
US20120100208A1 (en) 2012-04-26
RU2020101129A3 (pl) 2021-09-24
RU2011148362A (ru) 2013-06-10
US20130172413A1 (en) 2013-07-04
RU2020101129A (ru) 2021-07-15
US20200000759A1 (en) 2020-01-02
HK1165944A1 (en) 2012-10-12
RU2723555C2 (ru) 2020-06-16
US8709475B2 (en) 2014-04-29
HRP20171766T1 (hr) 2017-12-29
KR101343249B1 (ko) 2013-12-19
SG175389A1 (en) 2011-12-29
US8501225B2 (en) 2013-08-06
CN102458109B (zh) 2015-02-11
LT2424356T (lt) 2017-11-27
US9585856B2 (en) 2017-03-07
HUE051916T2 (hu) 2021-04-28
CA2759284C (en) 2016-06-21
ES2827204T3 (es) 2021-05-20
US9138415B2 (en) 2015-09-22
US10881632B2 (en) 2021-01-05
AU2010241571B2 (en) 2014-06-26
ES2647246T3 (es) 2017-12-20
SI2424356T1 (en) 2018-01-31
NZ627238A (en) 2016-02-26
BRPI1011876B1 (pt) 2020-03-31
EP2424356B1 (en) 2017-08-23
US9060983B2 (en) 2015-06-23
WO2010127103A1 (en) 2010-11-04
US11103477B2 (en) 2021-08-31
US20120225120A1 (en) 2012-09-06
CO6470838A2 (es) 2012-06-29
CN104856985A (zh) 2015-08-26
HUE034941T2 (en) 2018-03-28
US20130158120A1 (en) 2013-06-20
US20210212975A1 (en) 2021-07-15
US20130252989A1 (en) 2013-09-26
US20130156852A1 (en) 2013-06-20
US8445013B2 (en) 2013-05-21
US20170128402A1 (en) 2017-05-11
US20130165513A1 (en) 2013-06-27
US20130004572A1 (en) 2013-01-03
CY1119596T1 (el) 2018-04-04
DK2424356T3 (en) 2017-12-04
US10449172B2 (en) 2019-10-22
CN102458109A (zh) 2012-05-16
US20150238455A1 (en) 2015-08-27
MY157120A (en) 2016-05-13
EP2424356A1 (en) 2012-03-07
US8551521B2 (en) 2013-10-08
US20140017306A1 (en) 2014-01-16
US8642077B2 (en) 2014-02-04
HK1210717A1 (en) 2016-05-06
MX2011011538A (es) 2012-06-13
US20240148683A1 (en) 2024-05-09
US8613945B2 (en) 2013-12-24
US20130011471A1 (en) 2013-01-10
EP3278665A1 (en) 2018-02-07
CA2759284A1 (en) 2010-11-04
CN104856985B (zh) 2019-01-04
HK1250313A1 (zh) 2018-12-14
US20130079409A1 (en) 2013-03-28
EP3797591A1 (en) 2021-03-31
SG10201912687WA (en) 2020-02-27
PH12016500216B1 (en) 2018-01-29
PL3278665T3 (pl) 2021-02-22
SG10201605794PA (en) 2016-09-29
CY1123549T1 (el) 2022-03-24
US8445003B2 (en) 2013-05-21
US20140080909A1 (en) 2014-03-20
RU2538691C2 (ru) 2015-01-10
US20140235716A1 (en) 2014-08-21
US10010517B2 (en) 2018-07-03
US8617594B2 (en) 2013-12-31
LT3278665T (lt) 2020-12-10

Similar Documents

Publication Publication Date Title
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
EP2498988A4 (en) MEDICAL ARTICLES AND METHODS OF MANUFACTURING USING MISCIBLE COMPOSITION
PL2448581T3 (pl) Kompozycje terapeutyczne i odnośne sposoby ich stosowania
IL215497A0 (en) Oxadiazile derivatives and pharmaceutical compositions containing them
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
IL207724A0 (en) Cns pharmaceutical compositions and methods of use
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
IL247929B (en) Stable compositions of 595–sns and methods for their preparation
IL219018A (en) Radzolid Pharmaceuticals and Uses
HK1166953A1 (en) Compositions and methods of use